31 research outputs found
Effective Project Management of a Pan-African Cancer Research Network : Men of African Descent and Carcinoma of the Prostate (MADCaP)
CITATION: Odiaka, E. 2018. Effective Project Management of a Pan-African Cancer Research Network : Men of African Descent and Carcinoma of the Prostate (MADCaP). Journal of Global Oncology, 4:1-12, doi:10.1200/JGO.18.00062.The original publication is available at https://ascopubs.orgPurpose Health research in low- and middle-income countries can generate novel scientific knowledge
and improve clinical care, fostering population health improvements to prevent premature
death. Project management is a critical part of the success of this research, applying knowledge,
skills, tools, and techniques to accomplish required goals. Here, we describe the development
and implementation of tools to support a multifaceted study of prostate cancer in Africa, focusing
on building strategic and operational capacity.
Methods Applying a learning organizational framework, we developed and implemented a project
management toolkit (PMT) that includes a management process flowchart, a cyclical centerspecific
schedule of activities, periodic reporting and communication, and center-specific monitoring
and evaluation metrics.
Results The PMT was successfully deployed during year one of the project with effective component
implementation occurring through periodic cycles of dissemination and feedback to local
center project managers. A specific evaluation was conducted 1 year after study initiation to
obtain enrollment data, evaluate individual quality control management plans, and undertake risk
log assessments and follow-up. Pilot data obtained identified areas in which centers required
mentoring, strengthening, and capacity development. Strategies were implemented to improve
project goals and operational capacity through local problem solving, conducting quality control
checks and following compliancy with study aims. Moving forward, centers will perform quarterly
evaluations and initiate strengthening measures as required. Conclusion The PMT has fostered the development of both strategic and operational capacity
across project centers. Investment in project management resources is essential to ensuring
high-quality, impactful health research in low- and middle-income countries.https://ascopubs.org/doi/abs/10.1200/JGO.18.00062Publisher's versio
The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701
The OI Project - A New Institutional Identifier Registry
“The OI Project - A New Institutional Identifier Registry”
presented by Ed Pentz (Crossref) at the Joint Global Infrastructure Conference co-hosted by Crossref,
DataCite, and ORCID at the Korea Chamber of Commerce & Industry on 15 June
2017
Identifiers and Metadata Enable Connections
“Identifiers and Metadata Enable Connections” presented by Edward Pentz (Crossref) at the Identifiers and Intellectual Property Workshop co-hosted by Crossref, the OECD, and ORCID at the OECD in Paris, France on 22 June 2017
Isotope effects on the basicity of 2-nitrophenoxide, 2,4-dinitrophenoxide, hydroxide, and imidazole in protium oxide-deuterium oxide mixtures
ORCID License and Use Guidelines
This document describes how ORCID-created documents and resources, including our public data file, can be used under a CC0 license
20130326 ORCID Audit Committee Charter
ORCID's Audit Committee Charter was originally approved by the Board on 2013-03-26. Committee membership is updated annually and the most recent revision was on 2017-04-03